Dupixent Gets Room To Grow With New Indication In Chronic Rhinosinusitis
The new indication represents the third one for Sanofi/Regeneron's IL-4/IL-13 inhibitor, after atopic dermatitis and moderate to severe asthma.
You may also be interested in...
As earnings season reaches its peak, Merck, Lilly, Gilead, Amgen and Sanofi release their second quarter results. Business development remains a dominant theme.
Keeping Track: US FDA Closes Out First Half Of 2019 With CRL For Edsivo, But A Burst Of Supplemental Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Sanofi and Regeneron take a big step forward to building an allergy franchise off the back of newly released data from latest Dupixent trials in severe chronic rhinosinusitis with nasal polyps.